MARCHETTI, ANDREA
 Distribuzione geografica
Continente #
NA - Nord America 437
EU - Europa 416
AS - Asia 388
AF - Africa 41
SA - Sud America 5
Totale 1.287
Nazione #
US - Stati Uniti d'America 432
SG - Singapore 220
IT - Italia 155
CN - Cina 112
SE - Svezia 61
DE - Germania 46
CI - Costa d'Avorio 38
IE - Irlanda 28
FI - Finlandia 22
IN - India 22
CH - Svizzera 20
RU - Federazione Russa 18
JO - Giordania 16
NL - Olanda 14
BG - Bulgaria 13
GB - Regno Unito 12
AT - Austria 10
ID - Indonesia 8
FR - Francia 6
HK - Hong Kong 6
CA - Canada 4
PL - Polonia 4
BR - Brasile 3
LT - Lituania 3
TG - Togo 3
JP - Giappone 2
PK - Pakistan 2
BE - Belgio 1
CL - Cile 1
CO - Colombia 1
ES - Italia 1
GR - Grecia 1
LV - Lettonia 1
MX - Messico 1
Totale 1.287
Città #
Singapore 187
Santa Clara 83
Boardman 49
Abidjan 38
Chandler 36
Bologna 34
Dublin 27
Ashburn 24
Bern 19
Helsinki 19
Amman 16
Guangzhou 14
Sofia 13
Falkenstein 11
Turin 11
Milan 9
Nuremberg 9
Shanghai 9
Fairfield 8
Princeton 8
Rome 8
Southend 8
Beijing 7
Hyderabad 6
Jakarta 6
Hong Kong 5
Redmond 5
San Polo di Torrile 5
Vienna 5
Bari 4
Berlin 4
Boydton 4
Florence 4
Genoa 4
Rimini 4
Warsaw 4
Amsterdam 3
Bühl 3
Cambridge 3
Columbus 3
Enschede 3
Frankfurt am Main 3
Lappeenranta 3
Lomé 3
Modena 3
Moscow 3
Munich 3
Nanjing 3
Paris 3
San Diego 3
Seattle 3
Telgate 3
Terno d'Isola 3
Xi'an 3
Zhengzhou 3
Ann Arbor 2
Cagliari 2
Chengdu 2
Deiva Marina 2
Fuzhou 2
Gatineau 2
Gujrat 2
Harbin 2
Knivsta 2
Legnano 2
North Kuta 2
Norwalk 2
Phoenix 2
Pisa 2
Saint-Bonnet-près-Riom 2
Shenzhen 2
Shijiazhuang 2
Slough 2
São Paulo 2
Tokyo 2
Toronto 2
Verona 2
Athens 1
Bangalore 1
Baoding 1
Brussels 1
Buffalo 1
Cedar Knolls 1
Changsha 1
Chongqing 1
Des Moines 1
Dongguan 1
Dongying 1
Fort Worth 1
Handan 1
Hangzhou 1
Houston 1
Jiaozuo 1
Jinan 1
Jinzhong 1
Kunming 1
Langfang 1
Leicester 1
London 1
Los Angeles 1
Totale 831
Nome #
Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience 77
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis 70
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 58
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials 51
Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials 48
Bone targeting agents in patients with metastatic prostate cancer: State of the art 46
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 46
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience 44
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 42
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma 41
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 40
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 40
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 40
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 39
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 37
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma 37
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers 32
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study 31
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study 30
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 29
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer 28
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer 27
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1) 26
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy 26
Current androgen receptor antagonists under investigation for resistant prostate cancer 25
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study 24
Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials 24
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab 23
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? 21
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma 21
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 21
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma 20
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 20
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis 19
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma? 18
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis 18
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma 16
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: A critical overview of recent evidence 15
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study 15
Prostate cancer and novel pharmacological treatment options - what's new for 2022? 15
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? 15
Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives 14
Clinical outcomes and prognostic factors in patients with penile carcinoma: a sub-analysis from Meet-URO 23 (I-RARE) registry study 13
State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes 12
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study 12
Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial 11
Dual-energy spectral CT in renal cell carcinoma: dawn of a brand-new era? 3
18F-Fluorodeoxyglucose Uptake in PDGFRA-Mutant Gastrointestinal Stromal Tumors 1
Totale 1.381
Categoria #
all - tutte 6.842
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.842


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202112 0 0 0 0 0 0 0 0 0 7 0 5
2021/202282 0 0 1 3 2 1 6 20 5 3 29 12
2022/2023341 4 14 7 15 34 32 20 17 90 9 55 44
2023/2024218 19 36 20 14 18 27 6 16 15 12 21 14
2024/2025728 61 137 96 89 143 58 78 55 11 0 0 0
Totale 1.381